Although this review has focused on FLT3-mutated AML, venetoclax appears to be agnostic insofar as its effects on any particular mutation; patients with NPM1, DNMT3A, FLT3-ITD, and SRSF2 mutations have all demonstrated excellent responses. This evidence concerns the gene NPM1 and acute myeloid leukemia.